While the Yellow fever vaccine has been found highly effective when administered as a single dose, researchers have continued to examine the minimum dose requirements for seroconversion.
These researchers say the potential advantages of offering fractional doses are increased vaccinations and reduced under-vaccination, which have become a measurable health concern in the Region of the Americas over the past few years.
For example, 61 human cases of yellow fever were confirmed in the Region of the Americas in 2024, of which 30 were fatal (case fatality ratio, 50%).
Read More
